Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (226)	5/31/2002 10:21:07 AM
From: tuck	Read Replies (1) \| Respond to of 897

Peter, How old is this policy? I keep hearing that the law changed last year. The Ameritrade reference Michael cited hasn't been updated since '99. Then again, the one I cited is also of that vintage. As Michael has been showing, there are IPOs in the pipeline, including MitoKor. BLUE HP would have loved to short SGEN and NWBT as hedges; by the time the 30 days were up, the opportunity was gone. It'll be interesting to see if DOVP can bounce before that period is up. Might be worth an experimental paper short. In the under $5 department, there's NEOT, with its hypy history, wacky financing, and even wackier results in Parkinson's. They clearly are at sea regarding mechanism of action here, and I agree with "Scott" that it's too early in our understanding of neurotrophins to expect any success in that area. Of course, I'm a little late there; but I at least managed to follow it for a couple of years without buying it. Cheers, Tuck

To: Biomaven who wrote (226)	6/13/2002 1:24:07 PM
From: tuck	Read Replies (2) \| Respond to of 897

Peter, Granted that Yahoo! is not known for the integrity of its data, but it shows that as of May 8th, there was a small short interest in DOVP, which had IPO'd on April 23. biz.yahoo.com Now what do you say (easy to indulge in Yahoo! bashing)? Sure wish I could get a definitive answer on this issue. I'll slum around on the short threads again for the author of a post the SI search engine couldn't find who might be able to shed some light on it. Meanwhile, the Short Portfolio takes profits in DIO at current ask of $2.68. 66% profit in three months. Arguably, DIO was more a device company. Adding AGIX, which I think you own, to the watch list. Programs with a mixture of viability and tendency towards hype. Selling well above, cash, book, and other metrics that better biotechs are much closer to. Cheers, Tuck